112578 ⎘
Measuring or testing processes involving enzymes, nucleic acids or microorganisms ; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
METHOD FOR DETECTING THE PRESENCE, IDENTIFICATION AND QUANTIFICATION IN A BLOOD SAMPLE OF ANTICOAGULANTS WHICH ARE BLOOD COAGULATION ENZYMES INHIBITORS, AND MEANS FOR THE IMPLEMENTATION THEREOF
#2SERUM PREPARATION
#3EUGLOBULIN-BASED METHOD FOR DETERMINING THE BIOLOGICAL ACTIVITY OF DEFIBROTIDE
#4EUGLOBULIN-BASED METHOD FOR DETERMINING THE BIOLOGICAL ACTIVITY OF DEFIBROTIDE
#5TEST STRIPS FOR DETERMINING COAGULATION FACTOR ACTIVITIES
#6EUGLOBULIN-BASED METHOD FOR DETERMINING THE BIOLOGICAL ACTIVITY OF DEFIBROTIDE
#7COAGULATION AND FIBRINOLYSIS ASSAYS
#8METHOD FOR SEPARATING TARGET MOLECULES OR PARTICLES FROM FIBRINOGEN-CONTAINING SAMPLES INCLUDING BLOOD COMPONENTS
#9METHOD AND DEVICE FOR DETECTING TRANSGLUTAMINASES
#10EUGLOBULIN-BASED METHOD FOR DETERMINING THE BIOLOGICAL ACTIVITY OF DEFIBROTIDE
#11CLINICAL DECISION SUPPORT SYSTEM
#12METHODS FOR TESTING ANDEXANET POTENCY
#13DEVICES AND METHODS FOR MEASURING VISCOELASTIC CHANGES OF A SAMPLE
#14METHODS AND PRODUCTS FOR IN VIVO ENZYME PROFILING
#15HEPARIN-INSENSITIVE ASSAY FOR FACTOR XIa
#16Universal Calibration Method for Assaying Enzymatic Inhibitors
#17APTAMER BASED SYSTEM TO QUANTIFY ANTI-THROMBIN III IN BLOOD
#18METHODS AND KITS FOR IDENTIFYING THROMBUS ORIGIN AND OPTIMIZING POST-ISCHEMIC EVENT TREATMENT
#19ASSAYS FOR DETERMINING PLASMA KALLIKREIN SYSTEM BIOMARKERS
#20DETERMINATION OF INTERFERENTS IN A SAMPLE
#21LOW-VOLUME COAGULATION ASSAY
#22Methods and products for in vivo enzyme profiling
#23NMR DETECTION OF COAGULATION TIME
#24METHOD FOR DETECTING THE PRESENCE, IDENTIFICATION AND QUANTIFICATION IN A BLOOD SAMPLE OF ANTICOAGULANTS WHICH ARE BLOOD COAGULATION ENZYMES INHIBITORS, AND MEANS FOR THE IMPLEMENTATION THEREOF
#25METHOD FOR PURIFYING AND QUANTIFYING THROMBIN AND ITS DEGRADATION POLYPEPTIDES
#26Use of a global assay of coagulation and fibrinolysis to aide in thromboembolism
#27Euglobulin-based method for determining the biological activity of defibrotide
#28Euglobulin-based method for determining the biological activity of defibrotide
#29SYSTEMS AND METHODS FOR EVALUATING AN ABILITY OF A BLOOD SAMPLE TO COAGULATE, CLOT, AND/OR OCCLUDE
#30IMPROVED DETECTION OF ANTICOAGULANTS IN BODY FLUIDS
#31Test strips for determining coagulation factor activities
#32Device and process for sample preparation
#33Detection of Reversal of an Anticoagulant Using a Clotting Assay
#34METHOD FOR ASSAYING D-DIMERS SPECIFIC TO VENOUS THROMBOEMBOLISM AND USE THEREOF FOR DIAGNOSING PULMONARY EMBOLISM AND DEEP VENOUS THROMBOSIS
#35METHOD FOR SEPARATING TARGET MOLECULES OR PARTICLES FROM FIBRINOGEN-CONTAINING SAMPLES INCLUDING BLOOD COMPONENTS
#36Methods and products for in vivo enzyme profiling
#37Diagnostic kit for viscoelastic analysis and uses and methods thereof
#38LUPUS ANTICOAGULANT (LA) MIXING METHOD AND KIT WITH REDUCED FACTOR DEFICIENCY EFFECT AND REDUCED INHIBITOR INTERFERENCE FOR IDENTIFYING LA ASSOCIATED WITH ANTIPHOSPHOLIPID SYNDROME
#39FIBRINOGEN TEST
#40METHOD FOR DIAGNOSING HAEMOSTASIS DISORDERS USING ACTIVATED CHARCOAL
#41Apparatus and Method for Detecting and Correcting Blood Clot Events
#42Clotting composition
#43Device for monitoring the spatial and temporal dynamics of thrombin
#44COAGULATION AND FIBRINOLYSIS ASSAYS
#45Euglobulin-based method for determining the biological activity of defibrotide
#46USE OF C4BP-ALPHA PROTEIN IN HUMAN SERUM TO PREDICT CLOPIDOGREL RESISTANCE AND ITS CLINICAL APPLICATION AS A NOVEL BIOMARKER
#47Factor IX variants with clotting activity in absence of their cofactor and/or with increased F.IX clotting activity and their use for treating bleeding disorders
#48Incrementally optimized pharmacokinetic and pharmacodynamic model
#49Method for purifying and quantifying thrombin and its degradation polypeptides
#50Reagent for determination of coagulation time, production method therefor, reagent kit, and method for determination of coagulation time
#51Detection and classification of an anticoagulant using a clotting assay
#52Device and process for sample preparation
#53SERUM PREPARATION
#54Test strips for determining coagulation factor activities
#55Devices and methods for measuring viscoelastic changes of a sample
#56Method for determining fibrinogen and automatic analyzer
#57Thrombogenicity test apparatus and associated methods
#58DETERMINATION OF INTERFERENTS IN A SAMPLE
#59Characterization of subvisible particles using a particle analyzer
#60NON-BIOHAZARDOUS SOLUTIONS AND METHODS FOR TESTING ANALYSERS
#61Competition Test of an Enzyme Substrate with Internal Compensation for Enzyme Activity
#62Assay to measure factor Xa inhibitors
#63NMR DETECTION OF COAGULATION TIME
#64Methods for testing effectiveness of a von Willebrand factor used in treating von Willebrand disease (VWD)
#65Viscoelastic analysis in patients with disease associated with cardiovascular system
#66Universal Calibration Method for Assaying Enzymatic Inhibitors
#67METHOD FOR QUANTIFYING COGNITIVE DYSFUNCTION DISEASE BIOMAKER USING MASS SPECTROMETRY AND MASS SPECTROMETER
#68Compounds and methods for stabilizing thrombin activity
#69EUGLOBULIN-BASED METHOD FOR DETERMINING THE BIOLOGICAL ACTIVITY OF DEFIBROTIDE
#70Methods and products for in vivo enzyme profiling
#71Factor IX variants with clotting activity in absence of their cofactor and/or with increased F.IX clotting activity and their use for treating bleeding disorders
#72Apparatus and Method to Determine Stroke Subtype
#73Blood characteristic measurement
#74Method for determining blood specimen
#75Chemiluminescence-based haemostasis assay
#76Method for purifying and quantifying thrombin and its degradation polypeptides
#77Diagnostic kit for viscoelastic analysis and uses and methods thereof
#78SYSTEMS AND METHODS FOR MULTIPLEXED HEMOSTASIS TEST PANELS
#79Assessment of cardiac health and thrombotic risk in a patient
#80Thrombin-thrombomodulin fusion proteins as protein C activators
#81NOVEL lNHIBITORS OF THE ENZYME ACTIVATED FACTOR XII (FXIIA)
#82Method of detecting platelet activating antibodies that cause heparin-induced thrombocytopenia/thrombosis
#83Method for evaluating coagulation ability of blood specimen, and reagent, reagent kit and device to be used therein
#84NOVEL DIAGNOSTIC AND THERAPEUTIC TARGET IN INFLAMMATORY AND/OR CARDIOVASCULAR DISEASES
#85METHOD FOR SEPARATING TARGET MOLECULES OR PARTICLES FROM FIBRINOGEN-CONTAINING SAMPLES INCLUDING BLOOD COMPONENTS
#86Identification of novel disease states using viscoelastic analysis in the presence of a thrombolytic agent
#87Method and kit for identifying lupus anticoagulant (LA) associated with antiphospholipid syndrome
#88Clotting composition
#89Device and process for sample preparation
#90Reagent for prothrombin time measurement, method for production thereof, and method for measurement of prothrombin time
#91Test strips for determining coagulation factor activities
#92Methods of measuring adamts 13 activity
#93Assessment of blood coagulation using an acoustic radiation force based optical coherence elastography (ARF-OCE)
#94Assay to determine anticoagulants in blood or blood plasma
#95NANOSENSOR FOR ASSESSING THROMBIN INHIBITORS
#96LOW-VOLUME COAGULATION ASSAY
#97High-selectivity contact activation inhibitor based on infestin-4
#98Method for assaying a protease
#99Methods for universal determination of anticoagulant activity
#100Factor IX variants with clotting activity in absence of their cofactor and/or with increased F.IX clotting activity and their use for treating bleeding disorders
#101Method and system for characterizing the agglomeration or speed of particles contained in a liquid, such as blood particles
#102ENGINEERED GLYCOPROTEINS AND USES THEREOF
#103Methodologies and reagents for detecting fibrinolysis and hyperfibrinolysis
#104Assays for determining plasma kallikrein system biomarkers
#105COMPOSITION FOR THE DETERMINATION OF COAGULATION CHARACTERISTICS OF A TEST LIQUID
#106Method for purifying and quantifying thrombin and its degradation polypeptides
#107Method of detection of platelet-activating antibodies that cause heparin-induced thrombocytopenia/thrombosis
#108Sensor, detection method, detection system, and detection apparatus
#109METHOD FOR MONITORING ANTICOAGULANT THERAPY
#110Test strips for determining coagulation factor activities
#111REAGENT FOR MEASURING TOTAL PROTEIN S ACTIVITY
#112Method for thrombogenicity testing of implanted medical device
#113Assessment of cardiac health and thrombotic risk in a patient
#114Rare cell concentration
#115Protein assay
#116Method of increasing plasmin activity through antiplasmin conversion
#117Methods of measuring ADAMTS 13 activity
#118Detection and classification of an anticoagulant using a clotting assay
#119Analysis of direct factor Xa inhibitors
#120Liquid Factor VIII Formulations
#121Methods and apparatus for rapid monitoring of hemostatic state
#122NMR detection of coagulation time
#123Analysis of direct factor Xa inhibitors
#124Use of antidotes to coagulation inhibitors indicated in the prevention or treatment of thromboembolic pathologies
#125Measurement method for thrombin production
#126Methods for monitoring tight clot formation
#127Low-volume coagulation assay
#128Method for Detecting Endotoxins and/or 1,3-ß-D-Glucans in a Sample
#129LYOPHILISED DABIGATRAN
#130Method for evaluating blood coagulation reaction
#131Device for monitoring spatial coagulation of blood and of components thereof
#132Method for measuring blood coagulation
#133Methods for dynamic visualization of clinical parameters over time
#134Euglobulin-based method for determining the biological activity of defibrotide
#135Nano-recombinant fibrinogen for fibrin sealants
#136Method of diagnosing and treating infectious disseminated intravascular coagulation
#137Simultaneous measurement of thrombin generation and clot strength in plasma and whole blood
#138Compounds and methods for stabilizing thrombin activity
#139Method for simultaneously determining multiple coagulation proteases
#1402-(2-hydroxybiphenyl-3-yl)-1-benzoimidazole-5-carboxamidine derivatives as factor VIIA inhibitors
#141COMPOUNDS FOR USE IN BOOSTING COAGULATION
#142Method for detecting the presence or absence of an antibiotic resistant pathogenic staphylococci in a test sample
#143Method for the production of human thrombin and uses thereof
#144METHOD AND REAGENT KIT FOR MEASURING ACTIVATED PARTIAL THROMBOPLASTIN TIME
#145Method for producing recombinant prothrombin, vector DNA, and reagent kit
#146TREATMENT OF COAGULOPATHY WITH HYPERFIBRINOLYSIS
#147METHOD FOR DETERMINING PROTEIN S ACTIVITY
#148METHODS OF DETECTION OF CANCER USING PEPTIDE PROFILES
#149Methods and products for in vivo enzyme profiling
#150Method for determining the spatiotemporal distribution of activity of a proteolytic enzyme in a heterogeneous system (variations), a device for realizing same and a method for diagnosing the defects in the hemostatic system on the basis of a change in the spatiotemporal distribution of activity of a proteolytic enzyme in a heterogeneous system
#151Determination of direct thrombin inhibitors in fluids like serum or urine
#152Method for assaying plasminogen in a liquid medium, associated compositions and kit
#153Anticoagulant antagonist and hemophilia procoagulant
#154Methods of testing effectiveness of a treatment for thromobotic thrombocytopenic purpura by measuring ADAMTS13-mediated in vivo cleavage of von Willebrand factor
#155System and method for detecting and monitoring proteolysis of protein matrices
#156Method of measuring blood coagulation time to detect lupus anticoagulants
#157Method for detecting lupus anticoagulants
#158Electrochemical determination of factor XA inhibitors
#159Assessment of cardiac health and thrombotic risk in a patient
#160INCREASE IN STORAGE LIFETIME OF A THROMBIN SENSOR
#161Low-volume coagulation assay
#162Assessment of Protein C Anticoagulant Pathway By Thrombin Generation Assay In The Presence of Endothelial Cells
#163Procedure for biphasic preparation of liposomes and application thereof in manufacturing diagnostic reagents
#164APPARATUS AND METHODS FOR ANALYZING FLUID VARIABLES
#165Determining blood coagulation characteristics using residual accumulative conductive energy
#166Testing of blood coagulation characteristics
#167Thrombin Substrate and Assay for Determining the Level of Bioactive Thrombin in a Sample
#168Chemiluminescence-based haemostasis assay
#169Method for determining the activity of a proteolytic coagulation factor in a sample
#170Method and system for characterizing the movement speed of particles contained in a liquid, such as blood particles
#171Methods for detecting an endotoxin using a horseshoe crab clotting enzyme
#172Analysis of direct factor Xa inhibitors
#173Serum preparation
#174Thrombin inhibitor
#175Characterization of subvisible particles using a particle analyzer
#176Methods for modeling protein stability
#177Method for separating target molecules or particles from fibrinogen-containing samples including blood components
#1782-(2-hydroxybiphenyl-3-yl)-1H-Benzoimidazole-5-carboxamidine derivatives as factor VIIA inhibitors
#179Factor IXa crystals, related complexes and methods
#180NOVEL DIAGNOSTIC AND THERAPEUTIC TARGET IN INFLAMMATORY AND/OR CARDIOVASCULAR DISEASES
#181Post protein hydrolysis removal of a potent ribonuclease inhibitor and the enzymatic capture of DNA
#182Post protein hydrolysis removal of a potent ribonuclease inhibitor and the enzymatic capture of DNA
#183Post protein hydrolysis removal of a potent ribonuclease inhibitor and the enzymatic capture of DNA
#184Compositions, Methods and Uses for Simultaneous Assay of Thrombin and Plasmin Generation
#185Kit for measuring the thrombin generation in a sample of a patient's blood or plasma
#186USE OF A SUBSTRATE IN A METHOD FOR MEASURING THE ACTIVITY OF AVAILABLE PROTEOLYTIC ENZYMES
#187USE OF A SUBSTRATE IN A METHOD FOR MEASURING THE ACTIVITY OF PROTEOLYTIC ENZYMES
#188Use of platelet activating factor acetylhydrolase as a biomarker for anaphylaxis
#189TREATMENT OF COAGULOPATHY WITH HYPERFIBRINOLYSIS
#190Controls and kit for thrombocyte activity tests
#191Method for monitoring anticoagulant therapy
#192Heparin-insensitive method for determining direct coagulation factor inhibitors
#193Method of determining factor XIII with the aid of plasma-based reference material
#194Method of determining factor XIII by means of NAD(P)H-analogues
#195Method of determining inhibitors of coagulation
#196Post protein hydrolysis removal of a potent ribonuclease inhibitor and the enzymatic capture of DNA
#197Method for simultaneously determining multiple coagulation proteases
#198Methods and Apparatus for Measuring Blood Coagulation
#199Determination of von Willebrand Factor cleavage by ADAMTS13
#200Method of Determining Enzymatic Activity in Biological Media
#201Assessment of cardiac health and thrombotic risk in a patient
#202Method for in vitro assay of soluble fibrin by generating specific degradation products
#203Lipoprotein lipase assay
#204BLOOD COAGULATION TIME PROLONGING AGENT
#205Optical detector for use in therapy
#206Lyophilised dabigatran
#207EARLY DETECTION OF PATHOGENS IN BLOOD
#208COMPOSITIONS, KITS AND METHODS FOR DETERMINING PLASMIN ACTIVITY
#209METHODS OF DETECTION OF CANCER USING PEPTIDE PROFILES
#210NMR detection of coagulation time
#211METHOD FOR THE FUNCTIONAL MEASUREMENT OF PLASMATIC THROMBODULINE ACTIVITY
#212Method and apparatus for detecting specific DNA sequences
#2132-(2-hydroxybiphenyl-3-yl)-1-benzoimidazole-5-carboxamidine derivatives as factor VIIa inhibitors
#214Method of quality control testing a Factor XIII containing sample
#215Method for in vitro assay of the circulating tissue factor, and use in the detection of coagulation diseases
#216Thrombin generation determination method
#217Activated partial thromboplastin time measuring reagent, activated partial thromboplastin time measuring method, and determination method for determining presence or absence of blood coagulation inhibitor
#218Method for quantitatively analyzing an anticoagulant in a sample
#219Protein assay
#220Time-course measurement of enzymatic activity corrected for impacts of disturbances relating to the reaction of the enzyme with a substrate
#221Method for determining thrombin activity
#222Kit for collecting blood, preferably peripheral blood, for the production of stem cells
#223METHODS OF SCREENING FOR COMPOUNDS THAT MODULATE TAFIA ACTIVITY, COMPOUNDS, AND METHODS OF USING THE COMPOUNDS
#224ANTICOAGULANT ANTAGONIST AND HEMOPHILLIA PROCOAGULANT
#225Methods for diagnosing endometriosis
#226Anticoagulation of human blood ex vivo
#227Diagnostic assay for anti-von Willebrand Factor cleaving protease (ADAMTS13) antibodies
#228Apparatus and methods for analyzing fluid variables
#229Methods of detection of factor XIa and tissue factor
#230Method for measuring the plasmine activity of microparticles present in a sample of blood or a blood component
#231APPARATUS AND METHOD FOR ELECTROCHEMICAL DETECTION
#232Method for assaying coagulation in fluid samples
#233Method for assaying coagulation in fluid samples
#234Methods and products for in vivo enzyme profiling
#235Thrombin substrate and assay for determining the level of bioactive thrombin in a sample
#236Compositions and Methods for Modulation of ADAMTS13 Activity
#237Methods of measuring ADAMTS13-mediated in vivo cleavage of von Willebrand factor and uses thereof
#238Coagulation and fibrinolytic cascades modulator
#239DETECTION OF A BLOOD COAGULATION ACTIVITY MARKER IN A BODY FLUID SAMPLE
#240Method for determining the course of proteolytic activity
#241Blood coagulation assays
#242Method of increasing plasmin activity through antiplasmin conversion
#243Assessment of patients with sepsis to determine a requirement for therapeutic intervention with an anti-inflammatory and/or anticoagulatory agent
#244Assay For Tissue Factor And Factor Vlla
#245Measuring thrombin activity in whole blood
#246Early detection of pathogens in blood
#247Mass spectrometric determination of blood enzyme activity
#248Detection of venous thromboembolic diseases by measurement of D-dimers and soluble fibrin levels
#249Immunoadsorption of anti-von Willebrand factor cleaving protease antibodies
#250Method for determining prothrombin time
#251Electrochemical determination of factor XA inhibitors
#252Method and kit for detecting condition in patient with disturbance of consciousness
#253PRO-CLOTTING ENZYME, AND METHOD FOR DETECTION OF ENDOTOXIN OR (1-3)-BETA-D-GLUCAN USING THE SAME
#254Protocol and apparatus for determining heparin-induced thrombocytopenia
#255Methods of detection of cancer using peptide profiles
#256Detection procedures for fibrinogen and/or fibrinogen derivatives
#257ASSAY FOR MEASURING FACTOR VIIa-ANTITHROMBIN COMPLEXES
#258Thromboplastin reagent with long-term stability
#259Assessment of cardiac health and thrombotic risk in a patient
#260Use of platelet activating factor acetylhydrolase as biomarker for anaphylaxis
#261HEMATOLOGICAL ASSAY AND KIT
#262Procedure for the determination of the activity of the protease which activates factor VII from protein solutions
#2632-(2-Hydroxybiphenyl-3-yl)-1H-Benzoimidazole-5-Carboxamidine Derivatives as Factor VIIA Inhibitors
#264Assay for low molecular weight heparin
#265Labeling enzyme
#266Methods for Optimizing Forming Vlla-Based Hemostatic Treatment
#267Methods and Apparatus for Measuring Blood Coagulation
#268Pharmaceutical preparation with RNA as hemostasis cofactor
#269Methods of screening for compounds that modulate TAFIa activity, compounds, and methods of using the compounds
#270Methods for diagnosing endometriosis
#271Affinity adsorbents for plasminogen
#272Blood coagulation accelerator and container for blood examination
#273Procedure for the determination of the reaction lag phase in an analyte-dependent reaction
#274Method for differentiating between factor XIII deficiency states and fibrinogen deficiency states by means of thrombelastographic techniques
#275Optical detector for enzyme activation
#276Method for determining coagulation activation and device for carrying out said method
#277Methods of treatment involving the protease for activating clotting factor VII
#278Methods and kits for detecting and measuring ADAMTS13/FXI complexes
#279Device and method for measuring properties of a sample
#280Method of detecting platelet thrombosis or organ failure
#281Methods of treating stroke
#282Polysaccharide-peptide conjugates for use as thrombin substrates
#283COMPOSITIONS, KIT AND ONE-STEP METHOD FOR MONITORING COMPOUNDS HAVING ANTI-FACTOR Xa AND/OR ANTI FACTOR IIa ACTIVITIES
#284Assay for determining factor viia inhibitor concentration in plasma samples
#285Hemostasis assay
#286Virally-safe factor VIII with a low content of higher multimers
#287Method and Device for Measuring an Enzymatic Activity in a Body Fluid
#288Monitoring heparin by microelectronic devices
#289Assays for Determining Anticoagulant Cofactor Activity
#290Pharmaceutical preparation with RNA as hemostasis cofactor
#291Diagnostic method for identifying carriers of the Marburg I variant of factor VII-activating protease (FSAP) on the basis of differential modulation of FSAP activity
#292Method of evaluating patient hemostasis
#293Method for determining the concentration of thrombin inhibitors
#294Methods of treating diseases with activated protein C
#295Low molecular weight heparin assay, system and reagent therefor
#296Membrane system for blood coagulation testing
#297Membrane system for blood coagulation testing
#298Compositions and methods for inhibiting platelet activation and thrombosis
#299Factor Xa-based heparin assay using a heparin-modifying component
#300Cross-beta structures on microbial organisms